15-12B 1 v218090_15-12b.htm Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 15
  
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
 
Commission File Number: 001-33340

Tongjitang Chinese Medicines Company
 (Exact name of registrant as specified in its charter)
 
5th Floor, Block B
Nanshan Medical Device Park
1019 Nanhai Avenue, Shekou, Nanshan District
Shenzhen, 518067 Guangdong Province
People’s Republic of China
(86755) 2667 0969
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
 
American Depositary Shares, each representing four Ordinary Shares, par value $0.001 per share
(Title of each class of securities covered by this Form)
 
None
(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)
 
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
Rule 12g-4(a)(1)
 
o
Rule 12g-4(a)(2)
 
o
Rule 12h-3(b)(1)(i)
 
x
Rule 12h-3(b)(1)(ii)
 
o
Rule 15d-6
 
o
 
Approximate number of holders of record as of the certification or notice date: 2

Pursuant to the requirements of the Securities Exchange Act of 1934, Tongjitang Chinese Medicines Company has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
 
 
Date: April 15, 2011
By:
/s/ Justin Chen
 
   
Justin Chen
 
   
Chief Operating Officer